Sirolimus DEB in Coronary Bifurcation Lesions

NARecruitingINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

March 18, 2021

Primary Completion Date

September 18, 2025

Study Completion Date

September 18, 2026

Conditions
Coronary Bifurcation Lesions
Interventions
DEVICE

Sirolimus drug-eluting coronary balloon catheter

Patients in experimental group will undergo PCI, using sirolimus drug-eluting coronary balloon catheter.Subjects without stent implantation were regularly treated with dual antiplatelet for 9 months after surgery. Subjects with stents were regularly treated with dual antiplatelet for 12 months after the surgery, in accordance with the applicable guidelines for percutaneous coronary intervention.

DEVICE

Paclitaxel drug-eluting coronary balloon catheter

Patients in control group will undergo PCI, using paclitaxel drug-eluting coronary balloon catheter.Subjects without stent implantation were regularly treated with dual antiplatelet for 9 months after surgery. Subjects with stents were regularly treated with dual antiplatelet for 12 months after the surgery, in accordance with the applicable guidelines for percutaneous coronary intervention.

Trial Locations (1)

200000

RECRUITING

Zhongshan Hospital, Fudan University, Shanghai

All Listed Sponsors
lead

Shenzhen Salubris Pharmaceuticals Co., Ltd.

INDUSTRY

NCT04896177 - Sirolimus DEB in Coronary Bifurcation Lesions | Biotech Hunter | Biotech Hunter